Cancer Stem Cells Refuse to be Linked to Linker Histone H1.0October 19, 2016It is widely known that tumor lesions harbor diverse subpopulations of cell types each genetically and phenotypically unique. However, it is not always clear which cell types are actually promoting or sustaining the tumor. Typically, tumors consist of two class of cells—a subpopulation of cells that are fully differentiated and possess little to none tumor […]
Two “Suite” Tools for Tackling Big Data in Cancer Epigenomics AnalysesOctober 4, 2016With all the new datasets available, making sense of epigenomics data can be like finding a needle in a hayfield, let alone a stack. Studies of epigenetics in human complex disease have been greatly aided by larger and larger databases, but identifying meaningful biological relationships using these databases is challenging given their size. Cancer studies […]
Reporter of Genomic Methylation Delivers Imprinting and Epigenome Editing InsightsOctober 3, 2016Here at EpiGenie we like to think of ourselves as reporters of genomic methylation, but two new studies from the lab of Rudolf Jaenisch at MIT give us a run for our money and demonstrate the utility of their reporter of genomic methylation (RGM). Using RGM, the talented group brings forth a deeper understanding of […]
DNA Methylation Detects Ovarian Cancer’s Tissue of OriginSeptember 13, 2016While epigenetic variation underlies the origin of many cancers, underlying epigenetic similarities can reveal cancer’s tissue of origin. High-grade serous ovarian cancer (HGSC) is the most common and serious type of epithelial ovarian cancer. However, there are two competing hypotheses about which tissue HGSC arises from. Ovarian surface epithelia (OSE) has been implicated, but the […]
The Sunnyside of Precision DNA Demethylation by dCas9-TET1September 2, 2016On its quests to edit the epigenome like no biotechnology ever has, our deactivated Cas9 (dCas9) hero has come across many powerful effectors. When seeking out precision DNA demethylation, it has previously seen a multi TET1 approach. This makes use of both a dCas9 and TET1 catalytic domain fusion (dCas9-TET1) and also sgRNA 2.0 to […]
